A Monoclonal Antibody Directed Against a Candida Albicans Cell Wall Mannoprotein Exerts Three Anti-C. Albicans Activities
Overview
Authors
Affiliations
Antibodies are believed to play a role in the protection against Candida albicans infections by a number of mechanisms, including the inhibition of adhesion or germ tube formation, opsonization, neutralization of virulence-related enzymes, and direct candidacidal activity. Although some of these biological activities have been demonstrated individually in monoclonal antibodies (MAbs), it is not clear if all these anti-C. albicans activities can be displayed by a single antibody. In this report, we characterized a monoclonal antibody raised against the main target of salivary secretory immunoglobulin A in the cell wall of C. albicans, which exerts three anti-C. albicans activities: (i) inhibition of adherence to HEp-2 cells, (ii) inhibition of germination, and (iii) direct candidacidal activity. MAb C7 reacted with a proteinic epitope from a mannoprotein with a molecular mass of >200 kDa predominantly expressed on the C. albicans germ tube cell wall surface as well as with a number of antigens from Candida lusitaniae, Cryptococcus neoformans, Aspergillus fumigatus, and Scedosporium prolificans. MAb C7 caused a 31.1% inhibition in the adhesion of C. albicans to HEp-2 monolayers and a 55.3% inhibition in the adhesion of C. albicans to buccal epithelial cells, produced a 38.5% decrease in the filamentation of C. albicans, and exhibited a potent fungicidal effect against C. albicans, C. lusitaniae, Cryptococcus neoformans, A. fumigatus, and S. prolificans, showing reductions in fungal growth ranging from 34.2 to 88.7%. The fungicidal activity showed by MAb C7 seems to be related to that reported by antibodies mimicking the activity of a killer toxin produced by the yeast Pichia anomala, since one of these MAbs also reacted with the C. albicans mannoprotein with a molecular mass of >200 kDa. Results presented in this study support the concept of a family of microbicidal antibodies that could be useful in the treatment of a wide range of microbial infections when used alone or in combination with current antimicrobial agents.
Monoclonal antibodies: From magic bullet to precision weapon.
Aboul-Ella H, Gohar A, Ali A, Ismail L, Mahmoud A, Elkhatib W Mol Biomed. 2024; 5(1):47.
PMID: 39390211 PMC: 11467159. DOI: 10.1186/s43556-024-00210-1.
Deciphering the role of female reproductive tract microbiome in reproductive health: a review.
Gao H, Liu Q, Wang X, Li T, Li H, Li G Front Cell Infect Microbiol. 2024; 14:1351540.
PMID: 38562966 PMC: 10982509. DOI: 10.3389/fcimb.2024.1351540.
Bioactive peptides: an alternative therapeutic approach for cancer management.
Ghadiri N, Javidan M, Sheikhi S, Tastan O, Parodi A, Liao Z Front Immunol. 2024; 15:1310443.
PMID: 38327525 PMC: 10847386. DOI: 10.3389/fimmu.2024.1310443.
Koskela S, Figueiredo C Braz J Microbiol. 2023; 54(4):2561-2570.
PMID: 37725261 PMC: 10689714. DOI: 10.1007/s42770-023-01118-8.
Antibodies to Combat Fungal Infections: Development Strategies and Progress.
Rabaan A, Alfaraj A, Alshengeti A, Alawfi A, Alwarthan S, Alhajri M Microorganisms. 2023; 11(3).
PMID: 36985244 PMC: 10051215. DOI: 10.3390/microorganisms11030671.